HRD + BRCA wild-type

Conclusion These results demonstrate an association between T-cell exhaustion and HRD. T-cell exhaustion is an independent predictor of disease outcome in HGSOC.

Sponsored by Takeda

The analysis included 50 OC MDT members. Respondents were mainly based in England (84%; 42/50). Most HCPs (68%; 19/28) used the DESKTOP-III criteria to identify candidates for secondary cytoreduction, with up to 30% of patients considered as eligible in 85% (23/27) of centres.

Platinum-sensitive patients typically received PARPi maintenance therapy, irrespective of HRD status. Most HCPs used DESKTOP-III criteria to determine secondary debulking candidates at first relapse.

P=N/A, N=400, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P=N/A, N=400, Not yet recruiting, AstraZeneca

On the other hand , subgroup analyses of Paola 1 indicated a greater benefit for the combination of olaparib and bevacizumab in patients at lower risk of recurrence, i.e., patients without residual disease after primary debulking surgery. Several ongoing trials (e.g., NIRVANA-1, AGO-OVAR 28/ENGOT-ov57) are currently evaluating the contribution of adding bevacizumab to PARPi and will provide further evidence on this subject. Moreover, the magnitude of benefit from the combination could also depend on the location and type of HR gene mutations, and additional research is warranted to deepen our knowledge of the predictive role of the exact “causes” behind HR deficiency.

A robust correlation between the Leuven HRD and Myriad test was observed. For HRD+ tumours, the academic Leuven HRD showed a similar difference in PFS and OS as the Myriad test.

The results suggest that PARPi have a meaningful clinical benefit in PSOC, HRD, BRACm, and also in HRP and PROC; however, the evidence is not sufficient to recommend their routine use and further studies are needed to expand their role in the HRP and PROC groups.

The HRD status can be identified as an independent significance in Chinese HGSOC patients treated with first-line platinum-based chemotherapy.

Niraparib + bev 1L maintenance demonstrated promising results in advanced OC.

This is firstly showing the HRD and PD-L1 status in Asian OC patients. The results showed all the PSR patients could benefit from Olaparib treatment, regardless of HRD status. Meanwhile the numerically different mPFS observed across different HRD status subgroups also indicated potential clinical utility of locally developed HRD assay.